Kirkland Counsels Boehringer Ingelheim on Alliance with Lilly
Kirkland & Ellis advised Boehringer Ingelheim on its amended and restated alliance agreement with Eli Lilly and Company (NYSE: LLY). The parties agreed to modernize their alliance and focus their combined expertise and investment on the continued development and commercialization of Jardiance® (empagliflozin) in type 2 diabetes, heart failure, and chronic kidney disease. Trajenta® (linagliptin) and Basaglar® (insulin glargine) continue to be part of the alliance, but on revised terms.
The Kirkland team was led by technology and IP transactions partner David MacDonald and associate Matt Darch.
